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VISUALIZATION AND QUANTIFICATION OF UPTAKE OF
11C-ACETATE IN PROSTATE CANCER AND IN BENIGN
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Visualization of prostate cancer with positron emission tomography (PET) using 2-
[18F]-2-deoxy-D-Glucose (FDG) as radiopharmaceutical is limited by the low uptake
of FDG in the tumor and by radioactivity excreted into the bladder. More specific
PET radiopharmaceuticals would be welcome. Carbon-11 labeled acetate (ACET) is
a radiopharmaceutical generally used for cardiac PET as it represents oxidative
metabolism. ACET PET has recently been proposed for tumor imaging of prostate
cancer. We studied the imaging and uptake of 11C-acetate in prostate cancer and in
benign prostatic hyperplasia using ACET PET.
METHODS:
Twelve patients with histologically proven prostate cancer and five patients with benign
hyperplasia of the prostate were included. PET images were performed with an ECAT
HR+ using 800 MBq ACET. Data acquisition was started at 5 minutes post injection.
Attenuation-corrected images were evaluated visually. Standardized uptake values
(SUV) were calculated of the benign prostate gland and of prostate cancer.
RESULTS:
The benign prostate was visualized with a SUV of  2.8 ± 0.9 (mean ± SD). The primary
tumor could be visualized with a SUV of  3.6 ± 1.5 (mean ± SD). The difference in
uptake was not significant. Non-specific uptake of ACET was noticed in the intestines
and in the bone marrow. Little to no radioactivity in the bladder was observed.
CONCLUSION:
Carbon-11 labeled acetate is avidly taken up in both prostate cancer and in benign
prostates. It  poorly discriminates cancer from benign prostatic hyperplasia. Non
specific uptake is seen in intestine and bone marrow. These results could confine
clinical application of ACET PET as a metabolic imaging technique in prostate cancer.
INTRODUCTION
Positron emission tomography (PET) using 18F-fluoro-2-deoxy-D-glucose (FDG) as
a radiopharmaceutical has been shown to be an accurate technique for tumor detection,
staging and monitoring of therapy in a number of malignant tumors
1
. So far, the
clinical experience with FDG-PET in prostate cancer is limited for two reasons: the
uptake of FDG in prostate cancer is low and FDG is rapidly excreted in urine, causing
an accumulation of activity in the bladder
2,3,4,5
. More specific radiopharmaceuticals
which are not excreted in urine would be welcome in prostate cancer imaging with
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PET. Carbon-11-choline was proposed as a radiopharmaceutical for imaging of prostate
cancer and is currently studied for its clinical use
6,7,8
.
Carbon-11 labeled acetate (ACET) has recently been reported as a new PET
radiopharmaceutical for tumor detection
9
. Acetate metabolism in tumor tissue is not
yet completely understood but an increased lipid synthesis is proposed
10
. This is
different from acetate metabolism in the heart, where acetate reflects oxidative
metabolism which is the basis for assessment of myocardial viability.
First results with ACET PET in patients with (advanced) prostate cancer were published
recently and showed visualization of the primary tumor and of metastatic sites
11
. We
also studied the potential of ACET PET in patients with newly onset prostate cancer
and in patients with benign prostatic hyperplasia, in a prospective study.
MATERIALS AND METHODS
PATIENTS
Twelve consecutive patients with histologically proven T1-T3 adenocarcinoma of
the prostate without known distant metastases participated in this study. The primary
tumor was staged clinically according to palpatory findings and transrectal ultrasound.
A MRI or a CT was performed to assess lymph node metastases preoperatively. In
addition, the uptake of ACET in the normal prostate was studied in five patients with
benign prostatic hyperplasia.
Approval from the Hospital Medical Ethics Committee was obtained. Patients were
informed about the purpose and hazards of the study both orally and in writing, and
gave their consent.
RADIOPHARMACEUTICALS
The 11C-acetate was produced from 11C-carbon dioxide using a Grignard reagent
12
with specific activities > 3700 GBq/mmol. The radiotracer was dissolved in 4 ml of
saline. The solution was isotonic, colorless and sterile with a radiochemical purity of
> 95%.
IMAGING PROTOCOL
To minimize post biopsy effects, all studies were performed at least 2 weeks after
transrectal biopsy. Prior to the PET study the subjects were fastened overnight with
exception of water and their usual medication. The PET studies were performed using
an ECAT Exact HR+ PET Camera (Siemens/CTI, Knoxville, TN, USA). A transmission
scan was performed over three bed positions (10 minutes per position), covering the
pelvis and lower part of the abdomen, immediately followed by intravenous injection
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of 800 MBq ACET. Data acquisition was started at 5 minutes after injection over the
same area for 7 minutes per bed position.
IMAGE RECONSTRUCTION AND ANALYSIS
Attenuation-corrected images were made using an iterative reconstruction algorithm
(ordered subset expectation maximization).  PET-images were analyzed by 2
independent experienced PET physicians, who were blinded for the clinical data. The
location of each lesion was marked on case record forms and qualitatively scored as
– (no uptake), + (low uptake, just above background), ++ (intermediate uptake, clearly
above background) or +++ (high uptake). Analysis of the preferential uptake of the
radiopharmaceutical was performed by calculating standardized uptake values (SUV)
from regions of interest (ROI) obtained from the attenuation corrected images. The
ROIs were visually drawn using the ROI tool in the standard ECAT software. (Siemens/
CTI Inc. Knoxville TN, USA).
HISTOLOGICAL EXAMINATION
Histology was studied on the operation specimens after prostatectomy and/or pelvic
lymph node dissection or after transurethral resection of the adenoma of the prostate
in case of benign prostatic hyperplasia. The operation specimens were processed
according to standard methods. Primary histological diagnosis was made upon H/E
stained sections with, if necessary, additional immunohistochemical staining to
optimize the histological diagnosis. Based on the histological examination the tumor
was staged in the patients with prostate cancer according to the 1997 TNM
classification of the International Union against Cancer (IUCC).
STATISTICAL ANALYSES
Statistical significance was determined by the Student‘s t-test. A p-value of < 0.05
was considered significant.
RESULTS
VISUALIZATION OF BENIGN PROSTATIC HYPERPLASIA
The characteristics of the patients with benign hyperplasia and the results are shown
in table 1. Physiological uptake of the radiopharmaceutical was noticed in the small
intestine and in bone marrow of  the vertebral column and pelvis. No accumulation of
radioactivity was seen in the bladder region. The SUV of ACET in the benign prostate
is 2.8 ± 0.9 (mean ± SD). Histology of the operation specimens excluded malignancy
and showed benign hyperplasia in all five patients.
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In figure 1  the ACET-PET images of patient number 13 with benign hyperplasia of
the prostate are presented. A focally increased uptake of ACET in both lobes of the
prostate gland is noticed.
VISUALIZATION OF PROSTATE CANCER
The characteristics of the patients with prostate cancer and the results are also shown
in table 1. The primary tumor could be visualized as a hot spot within the prostate
gland in all twelve patients. No patients had proven lymph node metastases after
pelvic lymph node dissection. In six patients a diffuse accumulation of radioactivity
Figure 1. Attenuation-corrected ACET-PET images of a patient with benign prostatic
hyperplasia with focal uptake of ACET in the peripheral zone of both prostatic lobes.
Figure 2. Attenuation-corrected ACET-PET images of a patient with pT2 N0 M0 prostate
carcinoma with focal uptake of ACET in the peripheral zone of both prostatic lobes.
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in bone marrow was observed. The SUV of ACET in the prostate tumor is 3.6 ± 1.5
(mean ± SD) (NS).
In figure 2 the ACET-PET images of patient number 8 with a pT2 pN0 M0 prostate
cancer are presented. In this patient a high, multi focal uptake in the prostate tumor is
observed.
DISCUSSION
The most widely used PET radiopharmaceutical in oncology is FDG. However, FDG
shows major drawbacks in prostate cancer. As the uptake of FDG in prostate cancer is
low, the differentiation between cancer and benign hyperplasia is not possible
5
.
Moreover, the radiotracer is excreted into the bladder. High levels of radioactivity in
the bladder interfere with radioactivity accumulation in the prostate area and can
mask small tumors or metastases in the pelvic area. Bladder irrigation does not solve
this problem completely
3,5
. To diagnose prostate cancer, more specific PET
radiopharmaceuticals which are not excreted into the bladder are needed.
ACET is proposed as a new radiopharmaceutical for PET imaging of tumors
9
.  So far,
ACET has been applied extensively as a tracer to assess regional blood flow and
oxidative metabolism in the myocardium. In tumor tissue, the metabolism of acetate
is not yet fully understood, but a non oxidative pathway is proposed. In different
types of tumor cells, 90% of the radiolabeled 14C activity from 1-14C-acetate is in-
vitro incorporated in lipids
10
. Within this lipid fraction, phosphatidylcholine is the
predominant metabolite. Shreve et al recently reported on the cellular metabolism of
1-14C-acetate in PC3 and LnCap prostate cancer cell lines, with similar results
13
. The
radiocarbon label is predominantly incorporated in phosphatidyl-choline and neutral
lipids of the cells. Phospholipids are basic components of cell membranes and
phosphatidylcholine metabolism is increased in tumor tissue. Therefore, the uptake
of ACET in tumor cells may reflect growth activity or proliferation by an enhanced
membrane synthesis
10
. This could be the physiological basis for tumor imaging with
ACET-PET but additional in vivo studies are necessary to prove this hypothesis.
In our study, ACET-PET is shown to be effective in visualizing the primary tumor
within the prostate with good contrast. Consistent with the previous reports we also
noticed minimal to no excretion of radioactivity in the urine
11,14
. However, the uptake
of acetate in the prostate of patients with benign prostate hyperplasia is also avid and
hardly different from the uptake in prostate cancer. These results are in corrobation
with the results presented recently by Seltzer et al
15
. They reported on seven healthy
volunteers a SUV of 3.3±1.8 (maximum ± SD) versus SUV of  4.5±1.4 (maximum ±
42
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SD) in primary prostate cancer. The uptake of acetate in benign prostate tissue is
difficult to explain. The enhanced lipid metabolism is probably not associated with
the cell membrane synthesis because of tumor growth only. To understand the uptake
mechanism further (in vivo) studies on acetate metabolism are required. However,
we expect that the uptake of ACET in benign prostate tissue is a limitation for clinical
application in those cases where the prostate is still in situ after therapy.
As was reported previously
14
, we also noticed uptake of ACET in the bone marrow in
patients with stage M0 prostate cancer. We also observed uptake of ACET in bone
marrow of patients with benign hyperplasia. The uptake of acetate in bone marrow
could be non specific only. It may be a limitation for clinical use of ACET-PET in
follow up of patients with metastatic disease.
Another radiopharmaceutical under study for imaging of cancer, and  accumulating
by the same metabolic pathway as proposed for acetate is 11C-choline (CHOL)
16
.
Choline, after phosphorylation to phosphatidylcholine, is an essential component of
the cell membrane
17
. Cancer is associated with up-regulation of the enzyme choline-
kinase which catalyses the phosphorylation of choline
18,19,20
. So far several studies on
CHOL-PET in prostate cancer show visualization of both the primary tumor as well
as metastatic sites with good contrast in the absence of urinary radioactivity
6,7,8
.
Nevertheless, the clinical value of CHOL-PET in prostate cancer has yet to be proven
in the context of current treatment schemes  and in the context of other imaging
modalities.
In conclusion,  ACET is avidly taken up in both prostate cancer and in prostates with
benign hyperplasia. It poorly discriminates cancer from BPH. Non specific uptake is
seen in the intestines and in bone marrow. These results could confine clinical
application of ACET-PET as a metabolic imaging technique in prostate cancer.
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